Literature DB >> 29040778

Multimodality Management of Recurrent Skull Base Chordomas: Factors Impacting Tumor Control and Disease-Specific Survival.

Shaan M Raza1, Diana Bell2, Jacob L Freeman1, David R Grosshans3, Gregory N Fuller2, Franco DeMonte1.   

Abstract

BACKGROUND: Limited data exist to guide the management of recurrent chordomas arising in the skull base.
OBJECTIVE: To determine factors affecting tumor control rates and disease-specific survival (DSS) in recurrent disease.
METHODS: A retrospective review was performed of 29 patients with 55 recurrences treated at our institution. Tumor and treatment factors were assessed for impact on freedom from progression (FFP; primary outcome) and DSS (secondary outcome).
RESULTS: Postradiotherapy disease failure was much more difficult to manage vs progression after surgery alone (15.9 vs 41.4 mo, P = .094). Distant metastases and, specifically, leptomeningeal disease at presentation were associated with poorer DSS and FFP (P < .05). For local progression after surgery alone, repeat resection (P < .05) improved median FFP. With postradiotherapy local failure, repeat resection did not confer any benefit (13.5 vs 17.6 mo, P > .05), while a trend towards improved FFP was seen with stereotactic radiosurgery (28.3 vs 16.2 mo, P = .233). For distant metastases, site-directed therapy (surgery or radiation) allowed for site control (P < .05) but did not affect FFP or DSS. Presentation with early progression <6 mo from previous treatment portended significantly worse DSS (19.3 vs 77.6 mo, P < .05).
CONCLUSION: There is a need for treatment of recurrent disease to be tailored to the pattern of tumor recurrence and previously received treatments. Postradiotherapy progression poses particular challenges given the apparent limited role of repeat resection alone. Stereotactic radiosurgery may have a role in this setting. While patients with systemic metastases appear to respond well to site-directed therapy, those with leptomeningeal disease have a dismal prognosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29040778     DOI: 10.1093/ons/opx201

Source DB:  PubMed          Journal:  Oper Neurosurg (Hagerstown)        ISSN: 2332-4252            Impact factor:   2.703


  3 in total

1.  Salvage Therapy for Local Progression following Definitive Therapy for Skull Base Chordomas: Is There a Role of Stereotactic Radiosurgery?

Authors:  Linton T Evans; Franco DeMonte; David R Grosshans; Amol J Ghia; Ahmed Habib; Shaan M Raza
Journal:  J Neurol Surg B Skull Base       Date:  2019-02-21

2.  Management of Recurrent or Progressing Skull Base Chondrosarcomas: Predictors of Long-Term Outcomes.

Authors:  Jonathan D Breshears; Franco DeMonte; Ahmed Habib; Paul W Gidley; Shaan M Raza
Journal:  J Neurol Surg B Skull Base       Date:  2020-02-07

3.  Clinical Outcomes Following Dose-Escalated Proton Therapy for Skull-Base Chordoma.

Authors:  Adam L Holtzman; Ronny L Rotondo; Michael S Rutenberg; Daniel J Indelicato; Alexandra De Leo; Dinesh Rao; Jeet Patel; Christopher G Morris; William M Mendenhall
Journal:  Int J Part Ther       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.